Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance Akari Therapeutics stock opened at $3.60 on Monday. Akari Therapeutics has a twelve month low of $2.81 and a […]
More Stories
5,096 Shares in Priority Technology Holdings, Inc. (NASDAQ:PRTH) Acquired by Deutsche Bank AG
Deutsche Bank AG purchased a new stake in shares of Priority Technology Holdings, Inc. (NASDAQ:PRTH – Free Report) in the...
Millennium Management LLC Decreases Stake in MetroCity Bankshares, Inc. (NASDAQ:MCBS)
Millennium Management LLC lowered its position in MetroCity Bankshares, Inc. (NASDAQ:MCBS – Free Report) by 22.0% in the fourth quarter,...
REE Automotive Ltd. (NASDAQ:REE) Shares Purchased by Millennium Management LLC
Millennium Management LLC lifted its stake in REE Automotive Ltd. (NASDAQ:REE – Free Report) by 57.5% in the 4th quarter,...
Millennium Management LLC Grows Stake in Donegal Group Inc. (NASDAQ:DGICA)
Millennium Management LLC raised its holdings in shares of Donegal Group Inc. (NASDAQ:DGICA – Free Report) by 170.8% during the...
Millennium Management LLC Increases Stock Position in Nkarta, Inc. (NASDAQ:NKTX)
Millennium Management LLC increased its position in Nkarta, Inc. (NASDAQ:NKTX – Free Report) by 98.8% during the fourth quarter, HoldingsChannel.com...
Smith Douglas Homes Corp. (NYSE:SDHC) Shares Acquired by Millennium Management LLC
Millennium Management LLC increased its position in shares of Smith Douglas Homes Corp. (NYSE:SDHC – Free Report) by 50.0% in...